Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Is it prime-time for CAR-T in myeloma?

Nina Shah • 7 Dec 2019
ASH 2019
Multiple Myeloma CAR-T

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, gives an overview of the CAR T-cell therapy landscape in multiple myeloma (MM) and what we can expect to see in the future. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Nina Shah

Representation of women in hematology and oncology 2:07
Representation of women in hematology and oncology
Nina Shah • 15 Jun 2024
T-Cell Engagers: targets, challenges and opportunity 19:39
T-Cell Engagers: targets, challenges and opportunity
Hermann Einsele et al. • 27 Mar 2022
NKTR-255 in multiple myeloma and NHL 1:28
NKTR-255 in multiple myeloma and NHL
Nina Shah • 10 Dec 2021
Reporting patient experiences during the KarMMa trial 2:15
Reporting patient experiences during the KarMMa trial
Nina Shah • 10 Dec 2021

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals